{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-24-000013","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.000836+00:00","generated_at":"2026-06-02T03:41:56.936655+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6","bullets":["SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.","Intensity will supply INT230-6 and provide up to approximately $3.0 million in funding for the study.","Indemnification: SAKK indemnifies Intensity for claims from its study duties; Intensity indemnifies SAKK for issues from drug manufacturing, packaging, labeling.","Term runs until final clinical study report; either party may terminate for material breach, negligible scientific value, safety, or significant recruitment delay (>12 months)."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-24-000013","json":"https://secwatch.observer/filing/0001567264-24-000013.json","markdown":"https://secwatch.observer/filing/0001567264-24-000013.md","text":"https://secwatch.observer/filing/0001567264-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/0001567264-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/intensity-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:41:56.936655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b115301e7d7e48fb45a4c2581e900de81d2d4b3","claim":"INTENSITY THERAPEUTICS, INC. entered into Collaboration Agreement with The Swiss Group for Cancer Research SAKK valued at funding in the amount of up to approximately $3.0 million (effective 2024-05-06).","evidence_excerpt":"On May 6, 2024, Intensity Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with The Swiss Group for Cancer Research SAKK (“SAKK”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000013/0001567264-24-000013-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"The Swiss Group for Cancer Research SAKK"},{"label":"Value","value":"funding in the amount of up to approximately $3.0 million"},{"label":"Effective","value":"2024-05-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}